ArticleJournal of Korean medical science2026
Risk-Based Survival Outcomes in Early-Stage Endometrial Cancer: Impact of Radiation Therapy.
Article in Journal of Korean medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough a new paradigm incorporating molecular and histological classifications has emerged, molecular classification is not routinely performed for all patients in real-world practice. Therefore, evaluating the impact of adjuvant radiation in early-stage endometrial cancer according to risk grouping without molecular classification remains important. This study aims to assess the prognostic impact of adjuvant radiation in intermediate-risk (IR) and high-intermediate-risk (HIR) groups, as defined by the 2021 European Society of Gynaecological Oncology (ESGO) guidelines.
methodsWe retrospectively reviewed the medical records of 131 patients with stage I or II endometrial cancer classified as IR or HIR. All patients underwent staging surgery between July 2004 and April 2020 and were followed until December 2023. The prognostic impact of adjuvant radiation on survival outcomes was evaluated using multivariable analysis with a Cox proportional hazards model.
resultsThe median age of patients was 59 years, and the median follow-up duration was 73.4 months. Of the 131 patients, 72 (55.0%) were classified as IR and 59 (45.0%) as HIR. Adjuvant radiation was administered to 98 patients, including 45 (62.5%) in the IR group and 53 (89.8%) in the HIR group. Tumor recurrence occurred in 12.5% of IR patients and 8.5% of HIR patients (
conclusionAccording to the 2021 ESGO risk classification without molecular profiling, adjuvant radiation was associated with a significant improvement in PFS in the HIR group, but not in the IR group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.